News

The first participants have been dosed in a clinical trial that’s testing some of Sionna Therapeutics’ investigational treatments for cystic fibrosis (CF). The Phase 1 study (NCT07035990) is testing SION-451 with either SION-2222 or SION-109 in healthy volunteers, with the main goal being to evaluate the safety…

Northwestern University scientists developed a wearable patch that could help cystic fibrosis (CF) patients manage their disease from home. A study showed that the patch, developed in collaboration with scientists at Epicore Biosystems, measured sweat chloride in test participants as effectively as the gold standard method for sweat chloride assessment…

The Food and Drug Administration (FDA) placed the U.S. portion of a Phase 2b trial of BX004, a treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF), on clinical hold because of questions about a third-party drug delivery device. The treatment’s developer, Biomx, believes the FDA’s…

In people with cystic fibrosis (CF), treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) may reduce the risk of CF-related liver disease (CFLD) progression, according to a real-world study in France. Rates of severe liver complications were significantly lower among people with CF who were followed during the period after Kaftrio …

Interim results from the first nine participants in a Phase 2 clinical trial testing Arcturus Therapeutics’ experimental inhaled therapy ARCT-032 in adults with cystic fibrosis (CF) are expected next month. The U.S.-based study, called LunairCF (NCT06747858), is still recruiting CF patients who aren’t eligible for CFTR…

A new noninvasive prenatal test for cystic fibrosis (CF) and three other inherited conditions, launched by Natera, uses a sample of the mother’s blood to screen fetal DNA. The test, called Fetal Focus, may be particularly useful when the baby’s biological father isn’t available for genetic testing to…

Persistent Pseudomonas aeruginosa infection in people with cystic fibrosis (CF) who have received treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) seems to be a main driver of lung inflammation, a new study found. Trikafta is a highly effective CFTR modulator. Researchers also observed an “all-or-none” pattern in infection clearance in most…

The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences is developing to treat bacterial lung infections in people with cystic fibrosis (CF). The regulatory agency granted CMTX-101 fast track designation, which aims to speed the development of new…

Almost 30% of cystic fibrosis (CF) patients who had a lung transplant in the U.S. were prescribed Trikafta after surgery, a recent analysis shows. Sinus disease and low body mass index (BMI), a measure of body fat that takes into account weight and height, were associated with receiving…

Grants that provide financial assistance for nutrition may help people with cystic fibrosis (CF) maintain a healthy body weight, according to a study whose findings emphasize clinicians’ role in making sure patients know about the resources available to them. “The results of our study highlight the importance of active…